Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 36, Issue 2, Pages 144-+Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.2017.75.9845
Keywords
-
Categories
Funding
- Memorial Sloan Kettering Cancer Center Support Grant [P30-CA008748]
- Instituto de Salud Carlos III [PI16/01371]
- Catherine England Leiomyosarcoma Fund
- Jill Effect
Ask authors/readers for more resources
Leiomyosarcoma (LMS) is one of the most common subtypes of soft tissue sarcoma in adults and can occur in almost any part of the body. Uterine leiomyosarcoma is the most common subtype of uterine sarcoma. Increased awareness of this unique histology has allowed for the development of drugs that are specific to LMS and has begun to shed light on the similarities and possible unique aspects of soft tissue and uterine LMS. In this review, we summarize the current understanding of the epidemiology, diagnosis, genomics, and treatment options for LMS. (c) 2017 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
